Benign Prostatic Hyperplasia Treatment Market Research Report Information By Therapeutic Class (Alpha Blockers, 5- Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others), By Therapy (Mono Drug Therapy and Combination Drug Therapy), and By Region (North America, Europe, Asia-Pacific, and Rest Of The World) – Market Forecast Till 2032

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.4.1. Primary Interviews and Information Gathering Process

3.4.2. Breakdown of Primary Respondents

3.5. Forecasting Modality

3.6. Market Size Estimation

3.6.1. Bottom-Up Approach

3.6.2. Top-Down Approach

3.7. Data Triangulation

3.8. Validation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Value Chain Analysis

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining Power of Suppliers

5.2.2. Bargaining Power of Buyers

5.2.3. Threat of New Entrants

5.2.4. Threat of Substitutes

5.2.5. Intensity of Rivalry

5.3. COVID-19 Impact Analysis

5.3.1. Market Impact Analysis

5.3.2. Regional Impact

5.3.3. Opportunity and Threat Analysis

6. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY THERAPEUTICS CLASS

6.1. Overview

6.2. Alpha blockers

6.3. 5- alpha reductase inhibitors

6.4. Phosphodiesterase-5 inhibitors

6.5. Others

7. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY THERAPY

7.1. Overview

7.2. Mono drug therapy

7.3. Combination drug therapy

8. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY REGION

8.1. Overview

8.2. North America

8.2.1. U.S.

8.2.2. Canada

8.3. Europe

8.3.1. Germany

8.3.2. France

8.3.3. U.K

8.3.4. Italy

8.3.5. Spain

8.3.6. Rest of Europe

8.4. Asia-Pacific

8.4.1. China

8.4.2. India

8.4.3. Japan

8.4.4. South Korea

8.4.5. Australia

8.4.6. Rest of Asia-Pacific

8.5. Rest of the World

8.5.1. Middle East

8.5.2. Africa

8.5.3. Latin America

9. COMPETITIVE LANDSCAPE

9.1. Overview

9.2. Competitive Analysis

9.3. Market Share Analysis

9.4. Major Growth Strategy in the Global Benign Prostatic Hyperplasia Treatment Market,

9.5. Competitive Benchmarking

9.6. Leading Players in Terms of Number of Developments in the Global Benign Prostatic Hyperplasia Treatment Market,

9.7. Key developments and Growth Strategies

9.7.1. New THERAPEUTICS CLASS Launch/Therapy Deployment

9.7.2. Merger & Acquisitions

9.7.3. Joint Ventures

9.8. Major Players Financial Matrix

9.8.1. Sales & Operating Income, 2022

9.8.2. Major Players R&D Expenditure. 2022

10. COMPANY PROFILES

10.1. Abbott Laboratories

10.1.1. Company Overview

10.1.2. Financial Overview

10.1.3. Therapeutics Class Offered

10.1.4. Key Developments

10.1.5. SWOT Analysis

10.1.6. Key Strategies

10.2. AbbVie (Allergan Plc)

10.2.1. Company Overview

10.2.2. Financial Overview

10.2.3. Therapeutics Class Offered

10.2.4. Key Developments

10.2.5. SWOT Analysis

10.2.6. Key Strategies

10.3. Astellas Pharma Inc.

10.3.1. Company Overview

10.3.2. Financial Overview

10.3.3. Therapeutics Class Offered

10.3.4. Key Developments

10.3.5. SWOT Analysis

10.3.6. Key Strategies

10.4. Boehringer Ingelheim Pharma GmbH & Co. KG

10.4.1. Company Overview

10.4.2. Financial Overview

10.4.3. Therapeutics Class Offered

10.4.4. Key Developments

10.4.5. SWOT Analysis

10.4.6. Key Strategies

10.5. Eli Lilly and Company

10.5.1. Company Overview

10.5.2. Financial Overview

10.5.3. Therapeutics Class Offered

10.5.4. Key Developments

10.5.5. SWOT Analysis

10.5.6. Key Strategies

10.6. GlaxoSmithKline plc.

10.6.1. Company Overview

10.6.2. Financial Overview

10.6.3. Therapeutics Class Offered

10.6.4. Key Developments

10.6.5. SWOT Analysis

10.6.6. Key Strategies

10.7. Merck & Co., Inc. (Merck Sharp & Dohme Corp)

10.7.1. Company Overview

10.7.2. Financial Overview

10.7.3. Therapeutics Class Offered

10.7.4. Key Developments

10.7.5. SWOT Analysis

10.7.6. Key Strategies

10.8. Pfizer Inc.

10.8.1. Company Overview

10.8.2. Financial Overview

10.8.3. Therapeutics Class Offered

10.8.4. Key Developments

10.8.5. SWOT Analysis

10.8.6. Key Strategies

10.9. Sanofi

10.9.1. Company Overview

10.9.2. Financial Overview

10.9.3. Therapeutics Class Offered

10.9.4. Key Developments

10.9.5. SWOT Analysis

10.9.6. Key Strategies

10.10. Teva Pharmaceutical Industries Limited

10.10.1. Company Overview

10.10.2. Financial Overview

10.10.3. Therapeutics Class Offered

10.10.4. Key Developments

10.10.5. SWOT Analysis

10.10.6. Key Strategies

11. APPENDIX

11.1. References

11.2. Related Reports

LIST OF TABLES

TABLE 1 GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, SYNOPSIS, 2018-2032

TABLE 2 GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, ESTIMATES & FORECAST, 2018-2032 (USD BILLION)

TABLE 3 GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY THERAPEUTICS CLASS, 2018-2032 (USD BILLION)

TABLE 4 GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY THERAPY, 2018-2032 (USD BILLION)

TABLE 5 NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY THERAPEUTICS CLASS, 2018-2032 (USD BILLION)

TABLE 6 NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY THERAPY, 2018-2032 (USD BILLION)

TABLE 7 NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD BILLION)

TABLE 8 U.S. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY THERAPEUTICS CLASS, 2018-2032 (USD BILLION)

TABLE 9 U.S. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY THERAPY, 2018-2032 (USD BILLION)

TABLE 10 CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY THERAPEUTICS CLASS, 2018-2032 (USD BILLION)

TABLE 11 CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY THERAPY, 2018-2032 (USD BILLION)

TABLE 12 EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY THERAPEUTICS CLASS, 2018-2032 (USD BILLION)

TABLE 13 EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY THERAPY, 2018-2032 (USD BILLION)

TABLE 14 EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD BILLION)

TABLE 15 GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY THERAPEUTICS CLASS, 2018-2032 (USD BILLION)

TABLE 16 GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY THERAPY, 2018-2032 (USD BILLION)

TABLE 17 FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY THERAPEUTICS CLASS, 2018-2032 (USD BILLION)

TABLE 18 FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY THERAPY, 2018-2032 (USD BILLION)

TABLE 19 ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY THERAPEUTICS CLASS, 2018-2032 (USD BILLION)

TABLE 20 ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY THERAPY, 2018-2032 (USD BILLION)

TABLE 21 SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY THERAPEUTICS CLASS, 2018-2032 (USD BILLION)

TABLE 22 SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY THERAPY, 2018-2032 (USD BILLION)

TABLE 23 U.K BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY THERAPEUTICS CLASS, 2018-2032 (USD BILLION)

TABLE 24 U.K BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY THERAPY, 2018-2032 (USD BILLION)

TABLE 25 REST OF EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY THERAPEUTICS CLASS, 2018-2032 (USD BILLION)

TABLE 26 REST OF EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY THERAPY, 2018-2032 (USD BILLION)

TABLE 27 ASIA PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY THERAPEUTICS CLASS, 2018-2032 (USD BILLION)

TABLE 28 ASIA PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY THERAPY, 2018-2032 (USD BILLION)

TABLE 29 ASIA PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD BILLION)

TABLE 30 JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY THERAPEUTICS CLASS, 2018-2032 (USD BILLION)

TABLE 31 JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY THERAPY, 2018-2032 (USD BILLION)

TABLE 32 CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY THERAPEUTICS CLASS, 2018-2032 (USD BILLION)

TABLE 33 CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY THERAPY, 2018-2032 (USD BILLION)

TABLE 34 INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY THERAPEUTICS CLASS, 2018-2032 (USD BILLION)

TABLE 35 INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY THERAPY, 2018-2032 (USD BILLION)

TABLE 36 AUSTRALIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY THERAPEUTICS CLASS, 2018-2032 (USD BILLION)

TABLE 37 AUSTRALIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY THERAPY, 2018-2032 (USD BILLION)

TABLE 38 SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY THERAPEUTICS CLASS, 2018-2032 (USD BILLION)

TABLE 39 SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY THERAPY, 2018-2032 (USD BILLION)

TABLE 40 REST OF ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY THERAPEUTICS CLASS, 2018-2032 (USD BILLION)

TABLE 41 REST OF ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY THERAPY, 2018-2032 (USD BILLION)

TABLE 42 REST OF WORLD BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY THERAPEUTICS CLASS, 2018-2032 (USD BILLION)

TABLE 43 REST OF WORLD BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY THERAPY, 2018-2032 (USD BILLION)

TABLE 44 REST OF WORLD BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD BILLION)

TABLE 45 MIDDLE EAST BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY THERAPEUTICS CLASS, 2018-2032 (USD BILLION)

TABLE 46 MIDDLE EAST BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY THERAPY, 2018-2032 (USD BILLION)

TABLE 47 AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY THERAPEUTICS CLASS, 2018-2032 (USD BILLION)

TABLE 48 AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY THERAPY, 2018-2032 (USD BILLION)

TABLE 49 LATIN AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY THERAPEUTICS CLASS, 2018-2032 (USD BILLION)

TABLE 50 LATIN AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY THERAPY, 2018-2032 (USD BILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET

FIGURE 4 GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, SHARE (%), BY THERAPEUTICS CLASS, 2022

FIGURE 5 GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, SHARE (%), BY THERAPY, 2022

FIGURE 6 GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, SHARE (%), BY REGION, 2022

FIGURE 7 NORTH AMERICA: BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, SHARE (%), BY REGION, 2022

FIGURE 8 EUROPE: BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, SHARE (%), BY REGION, 2022

FIGURE 9 ASIA-PACIFIC: BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, SHARE (%), BY REGION, 2022

FIGURE 10 REST OF THE WORLD: BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, SHARE (%), BY REGION, 2022

FIGURE 11 GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET: COMPANY SHARE ANALYSIS, 2022 (%)

FIGURE 12 ABBOTT LABORATORIES: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 13 ABBOTT LABORATORIES: SWOT ANALYSIS

FIGURE 14 ABBVIE (ALLERGAN PLC): FINANCIAL OVERVIEW SNAPSHOT

FIGURE 15 ABBVIE (ALLERGAN PLC): SWOT ANALYSIS

FIGURE 16 ASTELLAS PHARMA INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 17 ASTELLAS PHARMA INC.: SWOT ANALYSIS

FIGURE 18 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 19 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG: SWOT ANALYSIS

FIGURE 20 ELI LILLY AND COMPANY.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 21 ELI LILLY AND COMPANY.: SWOT ANALYSIS

FIGURE 22 GLAXOSMITHKLINE PLC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 23 GLAXOSMITHKLINE PLC.: SWOT ANALYSIS

FIGURE 24 MERCK & CO., INC. (MERCK SHARP & DOHME CORP): FINANCIAL OVERVIEW SNAPSHOT

FIGURE 25 MERCK & CO., INC. (MERCK SHARP & DOHME CORP): SWOT ANALYSIS

FIGURE 26 PFIZER INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 27 PFIZER INC.: SWOT ANALYSIS

FIGURE 28 SANOFI: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 29 SANOFI: SWOT ANALYSIS

FIGURE 30 TEVA PHARMACEUTICAL INDUSTRIES LIMITED: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 31 TEVA PHARMACEUTICAL INDUSTRIES LIMITED: SWOT ANALYSIS